<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4417">
  <stage>Registered</stage>
  <submitdate>7/03/2014</submitdate>
  <approvaldate>7/03/2014</approvaldate>
  <nctid>NCT02107807</nctid>
  <trial_identification>
    <studytitle>Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine</studytitle>
    <scientifictitle>A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-003573-28</secondaryid>
    <secondaryid>V87_26</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza, Human</healthcondition>
    <healthcondition>Flu, Human</healthcondition>
    <healthcondition>Flu, Avian</healthcondition>
    <healthcondition>Influenza</healthcondition>
    <healthcondition>Influenza A Virus, H5N1 Subtype</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Novartis Investigational H5N1 vaccine
Other interventions - Novartis Investigational H5N1 vaccine
Other interventions - Novartis Seasonal Influenza Vaccine
Other interventions - Novartis Seasonal Influenza Vaccine

Experimental: Arm 1: aH5N1 adult - aH5N1 healthy and non-healthy adults

Experimental: Arm 2: aH5N1 elderly - aH5N1 healthy and non-healthy elderly

Active Comparator: Arm 4: aTIV elderly - aTIV healthy and non-healthy elderly

Active Comparator: Arm 3: aTIV adult - aTIV healthy and non-healthy adults


Other interventions: Novartis Investigational H5N1 vaccine
2 doses of 0.5 ml, 3 weeks apart

Other interventions: Novartis Investigational H5N1 vaccine
2 doses of 0.5 ml, 3 weeks apart

Other interventions: Novartis Seasonal Influenza Vaccine
2 doses of 0.5 ml, 3 weeks apart

Other interventions: Novartis Seasonal Influenza Vaccine
2 doses of 0.5 ml, 3 weeks apart

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of subjects achieving seroconversion* - *seroconversion: (defined as HI =1:40 for subjects who were seronegative at baseline [day 1 HI titer &lt;1:10] or a minimum 4-fold increase in HI titer for subjects who were seropositive at baseline [day 1 HI titer
=1:10]) on day 43.</outcome>
      <timepoint>day 43</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Geometric mean ratios (GMRs) as determined by HI assay</outcome>
      <timepoint>day 43</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects with an HI titer =1:40</outcome>
      <timepoint>day 43</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Solicited and unsolicited adverse events - In pooled age groups 18 years of age and older subjects who are healthy or with underlying medical condition who have received aTIV or aH5N1 vaccine.</outcome>
      <timepoint>day 202</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric mean titers as determined by Hemagglutination Inhibition</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric mean titers as determined by Hemagglutination Inhibition</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric mean titers as determined by Hemagglutination Inhibition</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric mean titers as determined by Single Radial Hemolysis</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric mean titers as determined by Single Radial Hemolysis</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric mean titers as determined by Single Radial Hemolysis</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric Mean Ratio as determined by Hemagglutination Inhibition</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric Mean Ratio as determined by Hemagglutination Inhibition</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric Mean Ratio as determined by Single Radial Hemolysis</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geometric Mean Ratio as determined by Single Radial Hemolysis</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving seroconversion determined by HI - seroconversion is defined as HI =1:40 for subjects who were seronegative at baseline [day 1 HI titer &lt;1:10] or a minimum 4-fold increase in HI titer for subjects who were seropositive at baseline [day 1 HI titer =1:10]) on days 22</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving seroconversion determined by SRH - seroconversion (defined as SRH area =25 mm2 for subjects who were seronegative at baseline [day 1 SRH area =3.997 mm2] or a significant increase [at least 50% increase] in SRH area for subjects who were seropositive at baseline [SRH area &gt;3.997 mm2]) on days 22, 43</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving seroconversion determined by SRH - seroconversion is defined as SRH area =25 mm2 for subjects who were seronegative at baseline [day 1 SRH area =3.997 mm2] or a significant increase [at least 50% increase] in SRH area for subjects who were seropositive at baseline [SRH area &gt;3.997 mm2]) on days 22, 43</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with an HI titer =1:40</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with an HI titer =1:40</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with geometric mean area =25 mm2</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with geometric mean area =25 mm2</outcome>
      <timepoint>Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects with geometric mean area =25 mm2</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and female individuals 18 years of age and older at the time of enrollment who
             are mentally competent, willing and able to understand the nature and risks of the
             proposed study, and able to sign the consent form prior to study entry;

          -  Individuals who are able to comply with all study procedures and requirements;

          -  Healthy volunteers and volunteers specifically HIV positive, transplant recipients,
             cancer patients may be eligible;

          -  Please contact the site for additional eligibility criteria.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Individuals who are not able to follow all the required study procedures for the whole
             period of the study;

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the Investigator, may interfere with the subject's ability to
             participate in the study;

          -  Please contact the site for additional eligibility criteria.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>539</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>102, Novartis Investigational Site - Darlinghurst</hospital>
    <hospital>103, Novartis Investigational Site - Darlinghurst</hospital>
    <hospital>101, Novartis Investigational Site - Merewether</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2291 - Merewether</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mecklenburg-Vorpommern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen-Anhalt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Chieti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Parma</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Seqirus</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novartis Vaccines</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18
      through 60 years of age) and elderly (=61 years of age) subjects with and without
      immunosuppressive conditions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02107807</trialwebsite>
    <publication>Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001 Mar 21;19(17-19):2673-80.
Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.
Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/5f2ae0fb-53f1-48c2-aa19-9114765ba029. Capecchi, Pamela [corrected to Capecchi, Pier Leopoldo].
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Vaccines</name>
      <address>Novartis Vaccines</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>